Inspire Medical Systems

Inspire Medical Systems is committed to elevating and redefining the standard of care for Obstructive Sleep Apnea (OSA). Founded in 2007 and based in the United States, the company has developed the world’s first fully implanted neurostimulation device approved by the FDA for the treatment of OSA. The Inspire system utilizes established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient’s unique breathing patterns. This innovative approach is designed to reduce OSA severity and improve the quality of life for patients living with this challenging condition. In April 2020, Inspire Medical Systems received a $133.40M Post-IPO Equity investment. The investors involved in this round were SVB Leerink and Guggenheim Securities. With its focus on the Biotechnology and Health Care industries, the company has positioned itself at the forefront of a significant healthcare challenge, offering a potentially game-changing solution for patients with OSA.